<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04427228</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-2022</org_study_id>
    <nct_id>NCT04427228</nct_id>
  </id_info>
  <brief_title>Single vs Multi-fraction SRS Patients on Immunotherapy</brief_title>
  <official_title>MIGRAINE: RandoMized trIal of sinGle veRsus multifrAction radIosurgery oN immunothErapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is meant to compare different surgical approaches to brain cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multi-Fraction SRS superiority compared to single fraction SRS</measure>
    <time_frame>4 years</time_frame>
    <description>To determine if Multi-Fraction SRS will decrease the rate of radionecrosis when compared to single-fraction SRS for patients with small metastases and are on immunotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target metastasis progression</measure>
    <time_frame>4 years</time_frame>
    <description>Target metastasis progression will be assessed using adapted Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) consensus imaging criteria. In brief, progressive disease is defined as a ≥20% relative increase in the longest diameter (LD) of the target metastasis compared to its smallest LD recorded on study, with a minimum absolute increase of 5 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>4 years</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Any acute CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities, within 90 days of SRS completion (toxicity must be specified).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Any late CTCAE v5.0 CNS Grade 2+ and Grade 3+ toxicities, greater than 90 days from SRS completion (toxicity must be specified).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of individual metastases radionecrosis</measure>
    <time_frame>4 years</time_frame>
    <description>To compare the rates over time of individual metastases radionecrosis using a parametric survival analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of individual metastases rates of edema</measure>
    <time_frame>4 years</time_frame>
    <description>To compare rates over time of individual metastases rates of edema using a parametric survival analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Symptomatic Edema</measure>
    <time_frame>1 year</time_frame>
    <description>To compare rates of symptomatic edema at 3 months, 6 months, and 1 year.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to any distant intracranial failure</measure>
    <time_frame>4 years</time_frame>
    <description>Time to any distant intracranial failure (ie, appearance of brain metastasis at untreated site).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of any combination</measure>
    <time_frame>4 years</time_frame>
    <description>Time to initiation of any combination of death, salvage SRS, WBRT, or neurosurgical resection for intracranial failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery Single Treatment</intervention_name>
    <description>Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) &lt; 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.</description>
    <arm_group_label>ARM B</arm_group_label>
    <other_name>SRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery Three Treatments</intervention_name>
    <description>Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>SRS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Adult patients (≥ 18 years old) with an ECOG Performance Status 0-2 and a life
        expectancy of 3 months or more.

        ii. Histologically confirmed systemic malignancy with gadolinium contrast-enhanced MRI scan
        demonstrating 1-10 newly diagnosed intraparenchymal brain metastases.

        iii. Well-circumscribed, measureable intraparenchymal brain metastasis(s) with maximum
        tumor diameter ≤3.0 cm. If multiple metastases are present, the other(s) must not exceed
        3.0 cm in maximum diameter. At least one metastasis must be ≥ 0.5 cm in maximum diameter to
        be considered measurable disease.

        iv. Negative urine or serum pregnancy test done ≤ 21 days prior to CT simulation, for women
        of child bearing potential only.

        v. Ability to understand and willingness to sign a written informed consent document.

        vi. Must have received immunotherapy (PD-1/PD-L1 and/or CTLA-4 inhibitor(s)) within the
        past 6 months or plan on receiving immunotherapy within the next 1 month.

        vii. Must have a Gustave Roussy Immune Score (GRIm-Score) of 0 or 1
        (neutrophil-to-lymphocyte ratio &gt; 6 = 1 point, LDH &gt; Upper Limit of Normal = 1 point, and
        Albumin &lt; 3.5 g/dL = 1 point).

        Exclusion Criteria:

        i. Diagnosis of germ cell tumor or hematologic malignancy. ii. Metastases in the brain
        stem, midbrain, pons, medulla, or within 7 mm of the optic apparatus (optic nerves, chiasm
        and optic tracts).

        iii. Diagnosis of leptomeningeal disease. iv. Prior SRS to an immediately adjacent
        lesion(s) of interest or to the current lesion(s) of interest.

        v. Prior history of pseudoprogression or radionecrosis from cranial radiotherapy.

        vi. A neurosurgical resection cavity deemed too large by the radiation oncologist to be
        treated with a single fraction of stereotactic radiosurgery.

        vii. Contraindications to gadolinium contrast-enhanced MRI (eg, non-compatible pacemaker,
        eGFR &lt;30, gadolinium allergy).

        viii. A Gustave Roussy Immune Score (GRIm-Score) &gt; 1 (neutrophil-to-lymphocyte ratio &gt; 6 =
        1 point, LDH &gt; Upper Limit of Normal = 1 point, and Albumin &lt; 3.5 g/dL = 1 point).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Chmura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Onderdonk, MD</last_name>
    <phone>773-702-6870</phone>
    <email>bonderdonk@radonc.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Onderdonk, MD</last_name>
      <phone>773-702-6870</phone>
      <email>bonderdonk@radonc.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Chmura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Onderdonk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

